甘精胰岛素与癌症。 - Suppr

Suppr

超能文献

Insulin glargine and cancer.

作者信息

Hemkens Lars G, Bender Ralf, Grouven Ulrich, Sawicki Peter T

出版信息

Lancet. 2009 Nov 21;374(9703):1743-4; author reply 1744. doi: 10.1016/S0140-6736(09)62018-3.

DOI:10.1016/S0140-6736(09)62018-3

PMID:19932352

Abstract

摘要

相似文献

Insulin glargine and cancer.

Lancet. 2009 Nov 21;374(9703):1743-4; author reply 1744. doi: 10.1016/S0140-6736(09)62018-3.

Basal insulin glargine vs prandial insulin lispro in type 2 diabetes.

Lancet. 2008 Aug 2;372(9636):371-2; author reply 372. doi: 10.1016/S0140-6736(08)61153-8.

A possible link between insulin glargine and malignancy: the facts.

Cardiovasc J Afr. 2009 Jul-Aug;20(4):216-8; discussion 218-9.

[Insulin glargine and cancer: a storm in a glass of water?].

Rev Med Liege. 2009 Sep;64(9):440-5.

Insulin glargine (Lantus) and cancer risk.

Med Lett Drugs Ther. 2009 Aug 24;51(1319):67-8.

Insulin glargine and cancer: another side to the story?

Lancet. 2009 Aug 15;374(9689):521. doi: 10.1016/S0140-6736(09)61477-X.

Insulin glargine and cancer--an unsubstantiated allegation.

Diabetes Technol Ther. 2009 Aug;11(8):473-6. doi: 10.1089/dia.2009.1705.

Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir.

Curr Med Res Opin. 2006 Dec;22(12):2613-9. doi: 10.1185/030079906X154178.

The international study of insulin and cancer.

Lancet. 2010 Sep 4;376(9743):769-70. doi: 10.1016/S0140-6736(10)61374-8.

Insulin glargine and malignancy: an unwarranted alarm.

Lancet. 2009 Aug 15;374(9689):511-3. doi: 10.1016/S0140-6736(09)61307-6. Epub 2009 Jul 17.

引用本文的文献

The association between type 2 diabetes mellitus and women cancer: the epidemiological evidences and putative mechanisms.

Biomed Res Int. 2015;2015:920618. doi: 10.1155/2015/920618. Epub 2015 Mar 19.

Protected graft copolymer (PGC) basal formulation of insulin as potentially safer alternative to Lantus® (insulin-glargine): a streptozotocin-induced, diabetic Sprague Dawley rats study.

Pharm Res. 2012 Apr;29(4):1033-9. doi: 10.1007/s11095-011-0646-8. Epub 2011 Dec 28.

Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients.

Diabetes Care. 2011 Sep;34(9):1965-71. doi: 10.2337/dc11-0699. Epub 2011 Jul 20.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Insulin glargine and cancer.

作者信息

Hemkens Lars G, Bender Ralf, Grouven Ulrich, Sawicki Peter T

出版信息

Lancet. 2009 Nov 21;374(9703):1743-4; author reply 1744. doi: 10.1016/S0140-6736(09)62018-3.

DOI:10.1016/S0140-6736(09)62018-3

PMID:19932352

Abstract

摘要

相似文献

Insulin glargine and cancer.

Lancet. 2009 Nov 21;374(9703):1743-4; author reply 1744. doi: 10.1016/S0140-6736(09)62018-3.

Basal insulin glargine vs prandial insulin lispro in type 2 diabetes.

Lancet. 2008 Aug 2;372(9636):371-2; author reply 372. doi: 10.1016/S0140-6736(08)61153-8.

A possible link between insulin glargine and malignancy: the facts.

Cardiovasc J Afr. 2009 Jul-Aug;20(4):216-8; discussion 218-9.

[Insulin glargine and cancer: a storm in a glass of water?].

Rev Med Liege. 2009 Sep;64(9):440-5.

Insulin glargine (Lantus) and cancer risk.

Med Lett Drugs Ther. 2009 Aug 24;51(1319):67-8.

Insulin glargine and cancer: another side to the story?

Lancet. 2009 Aug 15;374(9689):521. doi: 10.1016/S0140-6736(09)61477-X.

Insulin glargine and cancer--an unsubstantiated allegation.

Diabetes Technol Ther. 2009 Aug;11(8):473-6. doi: 10.1089/dia.2009.1705.

Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir.

Curr Med Res Opin. 2006 Dec;22(12):2613-9. doi: 10.1185/030079906X154178.

The international study of insulin and cancer.

Lancet. 2010 Sep 4;376(9743):769-70. doi: 10.1016/S0140-6736(10)61374-8.

Insulin glargine and malignancy: an unwarranted alarm.

Lancet. 2009 Aug 15;374(9689):511-3. doi: 10.1016/S0140-6736(09)61307-6. Epub 2009 Jul 17.

引用本文的文献

The association between type 2 diabetes mellitus and women cancer: the epidemiological evidences and putative mechanisms.

Biomed Res Int. 2015;2015:920618. doi: 10.1155/2015/920618. Epub 2015 Mar 19.

Protected graft copolymer (PGC) basal formulation of insulin as potentially safer alternative to Lantus® (insulin-glargine): a streptozotocin-induced, diabetic Sprague Dawley rats study.

Pharm Res. 2012 Apr;29(4):1033-9. doi: 10.1007/s11095-011-0646-8. Epub 2011 Dec 28.

Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients.

Diabetes Care. 2011 Sep;34(9):1965-71. doi: 10.2337/dc11-0699. Epub 2011 Jul 20.